# UCAR T-cell Therapy Targeting CD19/BCMA in Patients With r/r Myasthenia Gravis

> **NCT06933563** · EARLY_PHASE1 · NOT_YET_RECRUITING · sponsor: **Zhejiang University** · enrollment: 18 (estimated)

## Conditions studied

- Myasthenia Gravis

## Interventions

- **BIOLOGICAL:** UCAR T-cell group

## Key facts

- **NCT ID:** NCT06933563
- **Lead sponsor:** Zhejiang University
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-04
- **Primary completion:** 2026-04
- **Final completion:** 2027-11
- **Target enrollment:** 18 (ESTIMATED)
- **Last updated:** 2025-04-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06933563

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06933563, "UCAR T-cell Therapy Targeting CD19/BCMA in Patients With r/r Myasthenia Gravis". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT06933563. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*